Predictors of Lost to Follow-Up in Patients Being Treated for Proliferative Diabetic Retinopathy
Section snippets
Study Population
Approval from the Boston Medical Center Institutional Review Board was obtained prior to conducting this study, which was performed in accordance with the Health Insurance Portability and Accountability Act of 1996. Patients were identified for retrospective chart review using International Classifications of Diseases 9th and 10th revision codes for PDR and Current Procedural Terminology billing codes for IVI and PRP. Selection criteria for the study included males and females 18 years of age
Results
A total of 418 patients qualified for inclusion in the study, of which 256 patients (61%) were LTFU. Of patients who were LTFU, mean time of LTFU was 344 days (range, 181-1,078 days), with a median of 273 days. The mean (±SD) recommended follow-up time for visits prior to being LTFU was 3.3 (±2.1) months. Sixteen patients (3.83%) had a recommended follow-up time of greater than 6 months at least once during the study period. Descriptive characteristics of the authors' cohort are summarized in
Discussion
To date, this is the most comprehensive study examining risk factors for LTFU in patients being treated for PDR. Many of the variables assessed in this study have not been examined in this context previously in the medical literature. Specifically, variables unique to the present study include: primary language, history of mental illness and substance use; homelessness and food insecurity; insurance type; history of noncompliance and missed appointments in other clinics; history of NVI/NVG and
CRediT authorship contribution statement
Michael Green: Investigation, Formal analysis, Writing - original draft. Thomas Tien: Investigation, Writing - review & editing. Steven Ness: Conceptualization, Methodology, Writing - review & editing, Supervision.
References (30)
- et al.
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial
Lancet
(2017) - et al.
Vision outcomes following anti–vascular endothelial growth factor treatment of diabetic macular edema in clinical practice
Am J Ophthalmol
(2018) - et al.
Lost to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections
Ophthalmology
(2018) - et al.
Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor
Ophthalmology
(2019) - et al.
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
J Clin Epidemiol
(2004) - et al.
Patterns of adherence to diabetes vision care guidelines: baseline findings from the diabetic retinopathy awareness program
Ophthalmology
(2001) - et al.
Predictors of repeated “no-showing” to clinic appointments
Am J Otolaryngol
(2015) - et al.
Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial
JAMA
(2015) Ranibizumab for the treatment of wet AMD: a summary of real-world studies
Eye (Lond)
(2016)- et al.
Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema
Clin Ophthalmol
(2014)
Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial
JAMA Ophthalmol
Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage
Graefes Arch Clin Exp Ophthalmol
Co-morbidity in patients with sight-threatening diabetic retinopathy
Eye (Lond)
Divergent perceptions of barriers to diabetic retinopathy screening among patients and care providers, Los Angeles, California, 2014–2015
Prev Chron Dis
Patients’ adherence to recommended follow-up eye care after diabetic retinopathy screening in a publicly funded county clinic and factors associated with follow-up eye care use
JAMA Ophthalmol
Cited by (22)
Individual and Systems-Based Risk Factors for Diabetic Vitrectomy in an Urban Safety-Net Hospital
2023, Ophthalmology RetinaHealth Disparities in Lapses in Diabetic Retinopathy Care
2023, Ophthalmology ScienceTreatment of Proliferative Diabetic Retinopathy in 2023
2024, International Ophthalmology ClinicsEye Pain During Hemodialysis in Severe Proliferative Diabetic Retinopathy With Neovascular Glaucoma
2024, Journal of VitreoRetinal DiseasesTransition From Pediatric to Adult Nephrology Care: Program Report of a Single-Center Experience
2023, Canadian Journal of Kidney Health and DiseasePredicting ophthalmic clinic non-attendance using machine learning: Development and validation of models using nationwide data
2023, Clinical and Experimental Ophthalmology
Supplemental Material available at AJO.com.